Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

5

Revenue 2017

Merck & Co.

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck & Co.'s 2013 sales performance.

Merck

HTA guidance from NICE, the SMC and the AWMSG

NICE has said that the recently-approved combination of Merck &Co/MSD’s Keytruda with Pfizer’s Inlyta shouldn’t be. ... To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk.

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer Picks up approval as a first-line treatment for advanced cancer. The UK’s National Institute for Health and Care Excellence (NICE) has recommended Merck KGaA and Pfizer’s immunotherapy Bavencio ... number of cancer immunotherapies including Merck

Roche’s Tecentriq combo scores FDA approval for melanoma

Roche’s Tecentriq combo scores FDA approval for melanoma However, Roche is likely to face fierce competition from rival checkpoint inhibitors, namely Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo which have already been on the market

Sarah Matthew named as new Hanover Health Chair

Sarah Matthew named as new Hanover Health Chair Sarah Matthew co-founded Virgo Health in 2003, which grew into one of the leading international healthcare communication agencies.

AZ strengthens Daiichi Sankyo partnership with new ADC deal

AZ strengthens Daiichi Sankyo partnership with new ADC deal The NSCLC market is particularly lucrative, and is currently dominated by Merck &Co’s Keytruda (pembrolizumab), a PD-1 inhibitor which has become a standard treatment for newly-diagnosed NSCLC patients

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Covid-19 drives change in long-term conditions management
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home...
The importance of health literacy in patient recruitment materials
Have you ever read something that instantly made you want to read on? Or have you begun to read something, and eventually given up because it didn’t resonate with you?...
Secondary effects of COVID-19 on the healthcare system and patients
We are getting to the point where we need to start considering the long-term effects on the healthcare system when making decisions....

Infographics